electroCore, Inc. (ECOR) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals strong financial performance with significant revenue growth and improved gross margins. Despite increased expenses, adjusted EBITDA shows improvement. The Q&A highlights strategic growth plans in the VA and DTC channels, with new leadership potentially enhancing federal channel efficiency. While management's guidance was vague on some points, the overall sentiment is positive, supported by partnerships and product launches. These factors suggest a likely positive stock price movement, especially given the strong revenue growth and strategic initiatives.
Key Financial Performance
Revenue (Q4 2025) $9.2 million, up 31% year-over-year. Growth driven by expanded adoption of non-invasive pain therapeutics in the VA hospital system and strong Truvaga sales through e-commerce and affiliate networks.
Revenue (Full Year 2025) $32 million, up 27% year-over-year. Growth attributed to increased sales of gammaCore and Quell within the VA system and Truvaga general wellness products.
Prescription Device Revenue $26 million, up 23% year-over-year. Growth driven by gammaCore and Quell adoption in the VA hospital system.
General Wellness Revenue (Q4 2025) $1.4 million, up 31% year-over-year. Growth driven by Truvaga sales, with a seasonal increase in sales during the holiday season.
General Wellness Revenue (Full Year 2025) $5.5 million, up 97% year-over-year. Growth primarily driven by Truvaga sales, despite a one-time $500,000 order in Q3 2025.
Gross Margin (Full Year 2025) 87%, up from 85% in 2024. Improvement attributed to operational efficiencies.
Research and Development Expense $2.7 million, up $375,000 year-over-year. Increase due to development work on gammaCore Emerald and next-generation mobile application.
Selling, General, and Administrative Expense $38.2 million, up $7 million year-over-year. Increase driven by $3.8 million in personnel expenses, $800,000 in legal fees, $500,000 for one customer, $300,000 in IT investments, and $200,000 in transaction fees.
Net Loss (Full Year 2025) $14 million, compared to $11.9 million in 2024. Increase attributed to higher operating and other expenses.
Adjusted EBITDA Net Loss $8.7 million, compared to $9 million in 2024. Improvement reflects adjustments for acquisition-related items, bad debt reserve, and IP litigation.
Cash Equivalents and Marketable Securities $11.6 million as of December 31, 2025, compared to $12.2 million in 2024. Decrease due to operational and investment activities.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
gammaCore device: Supported by over 20 peer-reviewed publications and multiple randomized controlled trials, demonstrating significant reductions in migraine and cluster headache frequency, intensity, and duration. FDA-cleared for both acute and preventative treatments in adults and adolescents. Real-world adoption is growing, with measurable cost savings compared to standard care.
Truvaga: A wellness product focused on stress reduction, sleep quality, and emotional well-being. Gaining traction with recognition from major lifestyle publications and endorsements from influencers. Available through online retail outlets like Best Buy and RehabMart. Independent studies show high levels of user-reported calmness and sleep improvement.
Quell device: Supported by peer-reviewed research, including randomized controlled trials, demonstrating efficacy across multiple pain-related conditions, including fibromyalgia. Strengthens the clinical foundation of the portfolio.
VA hospital system: The largest customer, with 200 VA facilities purchasing gammaCore products, up from 170 a year ago. Approximately 13,400 VA patients received gammaCore devices, representing roughly 2% penetration of the addressable VA headache market. Expanded VA sales presence during 2025 by adding internal team members and contracted representatives.
General wellness channel: Fourth quarter revenue reached $1.4 million, representing 31% year-over-year growth. Full year general wellness revenue totaled $5.5 million, an increase of 97% compared to 2024. Truvaga sales drove this growth, with a 93% increase from 2024. Return on advertising spend improved to $2.10.
Leadership transition: CEO Daniel Goldberger announced retirement effective April 1, 2026. CFO Joshua Lev appointed as Interim President. Michael Fox to join as Chief Operating Officer in April 2026, bringing extensive experience in federal healthcare systems.
Financial performance: Fourth quarter 2025 revenue reached a record $9.2 million, up 31% year-over-year. Full year 2025 revenue was $32 million, a 27% increase from 2024. Gross margin improved to 87% from 85% in 2024. Adjusted EBITDA net loss for 2025 was $8.7 million, slightly improved from $9 million in 2024.
Indication expansion: Ongoing trials in PTSD, long COVID, substance abuse disorder, musculoskeletal pain, and concussions. Partnerships with NFL and NFLPA-funded research support long-term strategy for indication expansion.
Product development: Developing next-generation mobile applications to complement Truvaga and Quell, aiming for a more personalized and data-driven user experience. Potential for future recurring revenue opportunities.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Leadership Transition: The CEO's retirement and the appointment of an interim president and a new COO could lead to potential instability or disruption during the leadership transition period.
Regulatory and Legal Expenses: Increased legal fees, primarily associated with development activity, could strain financial resources.
Operating Expenses: Total operating expenses increased significantly, driven by higher personnel, legal, and marketing costs, which could impact profitability.
Net Loss: The company reported a net loss of $14 million for 2025, an increase from the previous year, which could affect investor confidence and financial stability.
VA System Dependency: A significant portion of revenue comes from the VA system, making the company vulnerable to changes in federal healthcare policies or VA purchasing decisions.
Return Rates: Return rates for e-commerce platforms have increased slightly, which could impact profitability and customer satisfaction.
Debt Financing: Interest expenses associated with term debt financing and other non-recurring expenses could impact financial health.
Market Penetration: Despite growth, the company has only achieved 2% penetration in the addressable VA headache market, indicating challenges in scaling adoption.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company expects full year 2026 revenue to grow approximately 30%, driven by continued adoption in the VA system and scaling of the wellness platform.
Product Development: Plans to introduce additional wellness offerings, including Quell Relief for lower extremity pain, and develop a next-generation mobile application to complement Truvaga and Quell, aiming for a more personalized and data-driven user experience.
Market Expansion: Focus on expanding adoption across the VA system and scaling the wellness platform, with a significant opportunity for growth in the VA headache market.
Operational Efficiency: Maintaining discipline around operating efficiency while investing in people, marketing, and product development to accelerate growth in 2026 and 2027.
Leadership Transition: Joshua Lev will serve as interim president and CFO, and Michael Fox will join as COO in April 2026 to accelerate adoption and expand commercial reach within federal healthcare systems.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Could you talk about the channels, specifically the VA and DTC for both gammaCore and Quell, and your expectations for 2026?
A:The VA channel has seen acceleration in 2025, with plans to grow by increasing the number of sales representatives (W-2 employees or 1099 network). A new commercial leader, Michael Fox, with extensive experience in federal channels, will join mid-April to help accelerate growth. For the DTC channel, the focus is on driving traffic to the website (truvaga.com) and increasing partnerships with affiliates and influencers. Partnerships like Miranda Kerr, RehabMart, and Best Buy are expected to drive growth in 2026.
Q:Can you talk about OUS channels and any expectations for 2026, including specific geographies?
A:NHS England remains the primary focus for OUS revenue, though there are bottlenecks due to prescription rules. There are distributors in Belgium with some reimbursement, but infrastructure development is ongoing. Updates will be provided as additional distribution partners and reimbursement opportunities arise.
Q:With the changes in management and the hiring of Michael Fox, what will be the new leadership dynamics?
A:Michael Fox will primarily focus on the VA and other federal/commercial systems, while Joshua Lev will handle day-to-day activities and the Truvaga business.
Q:Will there be any adjustments to the VA contracts with the onboarding of Michael Fox?
A:No immediate adjustments are expected. The VA contracts already list the products, and leadership changes do not typically affect the contracts. However, Michael Fox's experience may lead to potential improvements in contract efficiency.
Q:With Dan leaving, will there be a de-emphasis on the TAC-STIM product?
A:No, there will not be a de-emphasis. TAC-STIM remains a priority with a robust pipeline. Michael Fox's experience in federal systems may even accelerate revenue opportunities for TAC-STIM.
Q:Will the Quell Relief product be sold into the VA/DoD channels or general wellness, and when will it launch?
A:Quell Relief is an over-the-counter product planned for a soft launch in the first half of 2026. It will not be included in the 30% year-over-year revenue guidance and will be incremental.
Q:What is the goal for return on advertising spend (ROAS) in 2026?
A:The goal is to maintain ROAS above 2, with an average range of 2 to 2.5. The team actively monitors and adjusts media spend to optimize efficiency.
Q:What are the updates on insurance reimbursement coverage and barriers to broader adoption?
A:The focus is on Kaiser, where the company is on formulary and contract. Efforts are ongoing to develop KOLs and advocates within Kaiser. Success with Kaiser could lead to broader adoption by other managed care systems, but this is expected beyond 2026.
Q:Review of Unclear Management Responses
A:Management avoided giving specific guidance on VA growth for 2026, stating only general optimism about the existing team and Michael Fox's potential contributions. Additionally, they did not provide clear details on how they plan to overcome NHS England's prescription bottlenecks or specific timelines for broader insurance reimbursement adoption beyond Kaiser.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ACT PRESTO
Affiliates TrueMed
Buy RehabMart
CEO position
CFO
COVID
Chief Officer
Directors Lev
Dr
Lev Chief
condition
day
decision
device body
example
experience
foundation portfolio
investor
momentum
nVNS
outlet
peer
phase
place
position year
president
priority
progress
publication
reduction
research
role
search successor
sleep
step
study
term value
transition
trial
ECOR Transcript
electroCore, Inc. (ECOR) Q4 2025 Earnings Call Transcript
Positive3-19
The earnings call reveals strong financial performance with significant revenue growth and improved gross margins. Despite increased expenses, adjusted EBITDA shows improvement. The Q&A highlights strategic growth plans in the VA and DTC channels, with new leadership potentially enhancing federal channel efficiency. While management's guidance was vague on some points, the overall sentiment is positive, supported by partnerships and product launches. These factors suggest a likely positive stock price movement, especially given the strong revenue growth and strategic initiatives.
electroCore, Inc. (ECOR) Q3 2025 Earnings Call Transcript
Unknown11-5
The earnings call reflects mixed signals. Basic financial performance shows slight improvement in adjusted EBITDA net loss, but there's a delay in profitability. Product development is active, but with uncertainties in TAC-STIM and international revenue. Market strategy is cautious, with some success in VA channels. Expenses are increasing, impacting financial health. Shareholder returns are not addressed. Q&A reveals cautious expansion and litigation issues. Overall, the stock price reaction is likely neutral due to balanced positive and negative elements.
electroCore, Inc. (ECOR) Q2 2025 Earnings Call Transcript
Unknown8-6
The earnings call presents mixed signals. The VA revenue growth and Truvaga's year-over-year sales increase are positives. However, the sequential decline in Truvaga sales, increased operating expenses, and net loss raise concerns. The Q&A highlights uncertainties around patent litigation and unclear marketing spend impacts. While new product lines and integrations offer potential, the lack of specific guidance and profitability delays temper optimism. Given these factors, the stock price reaction is likely to remain neutral.
electroCore, Inc. (ECOR) Q1 2025 Earnings Call Transcript
Unknown5-7
The earnings call reveals mixed signals: strong revenue growth and gross margins, yet a significant cash burn and lack of 2025 guidance. The acquisition of NeuroMetrix adds complexity, while market access risks and operational challenges persist. The Q&A session highlighted management's lack of clarity on margin estimates and revenue growth projections, which could concern investors. Despite positive developments like the Truvaga expansion and distribution agreement, the absence of a shareholder return plan and cash flow risks temper optimism, leading to a neutral stock price prediction.
ECOR Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
